RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS

Purpose: To compare the possibility of using multiple-gated acquisition scan (MUGA) and 99mTc-MIBI GATE SPECT for evaluation and forecast of anthracycline–induced cardiotoxicity in breast cancer patients. material and methods. The study included 67 women (mean age – 44 ± 4.9 years) with breast cancer without significant pathology of the cardiovascular system. For the treatment of these patients used doxorubicin in dose of 50 mg/m²  per course in combination with various drugs. All patients were studied by MUGA (n=33) or GATE SPECT (n=34) before starting chemotherapy, at 1 hour after the first administration of doxorubicin and after the 4th course. results. After administration of doxorubicin at a dose of 50 mg/m² was found that 11 patients according MUGA and 14 patients according GATE SPECT had a significant (10 % or more) reduction in left ventricular ejection fraction (LVEF). Significant inhibition of systolic function in this patient group remained after the 4th course treatment. In the individual analysis of the MUGA and GATE SPECT results, registered after the administration of doxorubicin at a dose of 200 mg/m2, was revealed that the criterion of LVEF reduction (10 % or more) in response to the first dose of doxorubicin can predict the development of chronic cardiotoxicity. Conclusion. The MUGA and GATE SPECT can be applied with equal effectiveness for evaluation of acute and chronic anthracycline–induced cardiotoxicity in breast cancer patients. The decrease in LVEF (10 % or more) in response to the first dose of doxorubicin can predict the development of chronic cardiotoxicity.

1. Malignancies in Russia in 2014 (morbidity and mortality) / Eds. A.D. Kaprin, V.V. Starinskij, G.V. Petrova. М., 2016; 250. [in Russian]

2. Pisareva L.F., Odintsova I.N., Ananina O.A., Malinovskaya E.A., Stukanov S.L., Panferova E.V., Shivit-ool A.А., Cherdyntseva N.V. Bresat cancer incidence among indigenous peoples and newcomers of Siberia and Russian Far East. Health Care of the Russian Federation. 2012; 4: 37–41. [in Russian]

3. Choynzonov E.L., Balatskaya L.N., Dubsky S.V., Chizhevskaya S.Yu., Kupriyanova I.Ye., Krasavina E.A., Tuzikov S.A., Polishchyuk T.V., Popov D.N., Zhogina Zh.A., Musabaeva L.I., Slonimskaya E.M., Bekher O.A., Kolomiets L.A., Churuksaeva O.N., Molchanov S.V., Zhuikova L.D. Quality of life in cancer patients. Tomsk. Pechatnaya manufactura, 2011. 152 p. [in Russian]

4. Matjash M.G., Kravchuk T.L., Vysockaja V.V., Chernov V.I., Gol’dberg V.E. Non-anthracycline cardiotoxicity. Siberian Journal of Oncology. 2009; 5: 73–82. [in Russian]

5. National leadership on nuclear medicine / Eds. Yu.B. Lishmanov, V.I. Chernov. Tomsk, 2010; 1: 290. [in Russian]

6. Chernov V.I., Kravchuk T.L., Zel’chan R.V., Gol’dberg V.E. ECG-synchronized perfusion single photon emission computed tomography in the evaluation of myocardial doxorubicin cardiotoxicity. Nuclear Medicine and Radiation Safety. 2012; 4: 32–38. [in Russian]

7. Albini A., Pennesi G., Donatelli F., Cammarota R., De Flora S., Noonan D.M. Cardiotoxicity of Anticancer Drugs: The Need for CardioOncology and Cardio-Oncological Prevention. J Natl Cancer Inst. 2010 Jan 6; 102 (1): 14–25. doi: 10.1093/jnci/djp440.

8. Becher P.M., Lindner D., Miteva K., Savvatis K., Zietsch C., Schmack B., Van Linthout S., Westermann D., Schultheiss H.P., Tschöpe C. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and –receptor blockade. Hypertension. 2012 May; 59 (5): 949–57. doi: 10.1161/HYPERTENSIONAHA.111.183913.

9. Bovelli D., Plataniotis G., Roila F. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol. 2010 May; 21 Suppl 5: v277–82. doi: 10.1093/annonc/mdq200.

10. Colak M.C., Parlakpinar H., Tasdemir S., Samdanci E., Kose E., Polat A., Sarihan E., Acet A. Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol. 2012 Sep; 31 (9): 945–54. doi:10.1177/0960327112438288.

11. Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T., Criscitiello C., Goldhirsch A., Cipolla C., Roila F. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012 Oct; 23 Suppl 7: vii155–66. doi: 10.1093/annonc/mds293.

12. de Geus-Oei L.F., Mavinkurve-Groothuis A.M., Bellersen L., Gotthardt M., Oyen W.J., Kapusta L., van Laarhoven H.W. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med. 2011 Apr; 52 (4): 560–71. doi: 10.2967/jnumed.110.082784.

13. Drímal J., Zúrová-Nedelcevová J., Knezl V., Sotníková R., Navarová J. Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab. Neuro Endocrinol Lett. 2006 Dec; 27 Suppl 2: 176–9.

14. Elbl L., Vásová I., Navrátil M., Tomásková I., Jedlicka F., Chaloupka V., Vorlícek J. Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy. Vnitr Lek. 2006 Apr; 52 (4): 328–38.

15. Gayed I.W., Liu H.H., Yusuf S.W., Komaki R., Wei X., Wang X., Chang J.Y., Swafford J., Broemeling L., Liao Z. The Prevalence of Myocardial Ischemia After Concurrent Chemoradiation Therapy as Detected by Gated Myocardial Perfusion Imaging in Patients with Esophageal Cancer. J Nucl Med. 2006 Nov; 47 (11): 1756–62.

16. Gendlin G.E., Storozhakov G.I., Shuykova K.V. Acute cardiovascular events during antitumor drugs treatment: clinical cases. Clinical oncohematology. 2011; 4 (2): 155–164. [in Russian]

17. Lenneman A.J., Wang L., Wigger M., Frangoul H., Harrell F.E., Silverstein C., Sawyer D.B., Lenneman C.G. Heart Transplant Survival Outcomes for Adriamycin-Dilated Cardiomyopathy. Am J Cardiol. 2013 Feb 15; 111(4): 609–12. doi: 10.1016/j.amjcard.2012.10.048.

18. Perez E.A., Suman V.J., Davidson N.E., Kaufman P.A., Martino S., Dakhil S.R., Ingle J.N., Rodeheffer R.J., Gersh B.J., Jaffe A.S. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Sep 15; 22 (18): 3700–4. doi: 10.1200/JCO.2004.03.516.

19. Raj S., Franco V.I., Lipshultz S.E. Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment. Curr Treat Options Cardiovasc Med. 2014 Jun; 16 (6): 315. doi: 10.1007/s11936-014-0315-4.

20. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., Gerszten R.E., Halpern E.F., Passeri J., Kuter I., Scherrer-Crosbie M. Assessment of Echocardiog-raphy and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients treated with Anthracyclines, Taxanes and Trastuzumab. Circ Cardiovasc Imaging. 2012 Sep 1; 5 (5): 596–603. doi: 10.1161/CIRCIMAGING.112.973321.

21. Schirmer S.H., Degen A., Baumhäkel M., Custodis F., Schuh L., Kohlhaas M., Friedrich E., Bahlmann F., Kappl R., Maack C., Böhm M., Laufs U. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J. 2012 May; 33 (10): 1223–31. doi: 10.1093/eurheartj/ehr255.

22. Urbanová D., Urban L., Carter A., Maasova D., Mladosievicova B. Cardiac troponins – biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma. 2006; 53 (3): 183–90.

23. Wasielewski M., van Spaendonck-Zwarts K.Y., Westerink N.D., Jongbloed J.D., Postma A., Gietema J.A., van Tintelen J.P., van den Berg M.P. Potential genetic predisposition for anthracycline-associated cardiomyopathy in families withdilated cardiomyopathy. Open Heart. 2014 Jul 18; 1 (1): e000116. doi: 10.1136/openhrt-2014-000116.